Novo Nordisk A/S (NYSE:NVO) Shares Bought by Summit Trail Advisors LLC

Summit Trail Advisors LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 43.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,632 shares of the company’s stock after buying an additional 1,404 shares during the quarter. Summit Trail Advisors LLC’s holdings in Novo Nordisk A/S were worth $479,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Xponance Inc. purchased a new position in Novo Nordisk A/S in the 3rd quarter worth about $248,000. Bank of New York Mellon Corp grew its position in Novo Nordisk A/S by 97.1% during the third quarter. Bank of New York Mellon Corp now owns 863,598 shares of the company’s stock valued at $78,536,000 after purchasing an additional 425,392 shares in the last quarter. Brown Advisory Inc. lifted its position in Novo Nordisk A/S by 96.0% in the 3rd quarter. Brown Advisory Inc. now owns 107,860 shares of the company’s stock worth $9,809,000 after buying an additional 52,830 shares in the last quarter. Concord Wealth Partners boosted its stake in shares of Novo Nordisk A/S by 152.1% during the 3rd quarter. Concord Wealth Partners now owns 426 shares of the company’s stock valued at $39,000 after buying an additional 257 shares during the period. Finally, Pinnacle Wealth Management Advisory Group LLC raised its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pinnacle Wealth Management Advisory Group LLC now owns 3,002 shares of the company’s stock worth $273,000 after acquiring an additional 1,501 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $3.05 during mid-day trading on Tuesday, hitting $127.64. 1,625,345 shares of the company were exchanged, compared to its average volume of 4,811,845. The company has a market capitalization of $572.79 billion, a PE ratio of 43.87, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The business has a fifty day moving average of $127.22 and a 200 day moving average of $113.29. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.